GLAS supports €550m refinancing for Juvisé Pharmaceuticals

GLAS is pleased to announce the successful completion of a €550 million refinancing transaction for Laboratoires Juvisé Pharmaceuticals.

The GLAS team acted as Paying Agent, Calculation Agent, Registrar, Bondholder Representative Agent, Security Agent, and managed the Funds Flow Execution, ensuring a seamless closing across this multi-layered structure.

The transaction includes the refinancing of existing debt and the establishment of a new facility dedicated to future growth initiatives, including potential M&A opportunities.

This refinancing strengthens Juvisé Pharmaceuticals’ financial position, providing greater flexibility to advance its expansion strategy and supporting both its ongoing development and long‑term ambitions to broaden access to essential medicines.

About Juvisé Pharmaceuticals

Since its creation in 2008, Juvisé Pharmaceuticals has played a pivotal role in enhancing patient care by providing access to treatments with high medical value. Juvisé re-prioritized essential medicines in neurology, gastroenterology and oncology. Juvisé Pharmaceuticals is present through its products in more than 80 countries in the world on 5 continents and relocates 95% of its production in Europe.

About GLAS

GLAS was established in 2011 as an independent provider of institutional debt administration services. The company was originally created to provide the market a willing participant in complex loan restructuring transactions where many large institutions are reluctant to take swift and cooperative action. It offers a wide range of administration services developed specifically for the debt market.

GLAS is recognised as the premier independent, non-creditor, conflict-free provider of loan agency and bond trustee services, with excess of $800bn of assets under administration on a daily basis. For more information, contact media@glas.agency.